{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-043250","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2024-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.269400+00:00","generated_at":"2026-05-30T16:28:44.564439+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"ADMA Biologics affirms 2024-2025 guidance unaffected by auditor switch","bullets":["Management stated no anticipated impact to previously provided 2024-2025 financial guidance from auditor transition.","Statement made after market close on Oct 9, 2024, in discussions with analysts.","Auditor change described in separate Form 8-K filed on Oct 9, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-043250","json":"https://secwatch.observer/filing/0001140361-24-043250.json","markdown":"https://secwatch.observer/filing/0001140361-24-043250.md","text":"https://secwatch.observer/filing/0001140361-24-043250.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124043250/0001140361-24-043250-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124043250/ef20037117_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T16:28:44.564439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}